WO2000026247A8 - Ikaros isoforms and mutants - Google Patents

Ikaros isoforms and mutants

Info

Publication number
WO2000026247A8
WO2000026247A8 PCT/US1999/026274 US9926274W WO0026247A8 WO 2000026247 A8 WO2000026247 A8 WO 2000026247A8 US 9926274 W US9926274 W US 9926274W WO 0026247 A8 WO0026247 A8 WO 0026247A8
Authority
WO
WIPO (PCT)
Prior art keywords
ikaros
mutants
ikaros isoforms
isoforms
lymphoid cell
Prior art date
Application number
PCT/US1999/026274
Other languages
French (fr)
Other versions
WO2000026247A3 (en
WO2000026247A9 (en
WO2000026247A2 (en
Inventor
Fatih M Uckun
Mya L Crotty
Original Assignee
Parker Hughes Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Parker Hughes Inst filed Critical Parker Hughes Inst
Priority to CA002349417A priority Critical patent/CA2349417A1/en
Priority to JP2000579634A priority patent/JP2002531066A/en
Priority to AU18148/00A priority patent/AU1814800A/en
Priority to EP99961606A priority patent/EP1127070A2/en
Publication of WO2000026247A2 publication Critical patent/WO2000026247A2/en
Publication of WO2000026247A3 publication Critical patent/WO2000026247A3/en
Publication of WO2000026247A9 publication Critical patent/WO2000026247A9/en
Publication of WO2000026247A8 publication Critical patent/WO2000026247A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Specific Ikaros mutations, as well as the correlation of the presence of the specific Ikaros mutations and other wild-type non-DNA binding Ikaros isoforms with lymphoid cell abnormality is provided in the invention. Methods for detecting and treating lymphoid cell abnormality, including hematologic malignancy, are also provided.
PCT/US1999/026274 1998-11-05 1999-11-05 Ikaros isoforms and mutants WO2000026247A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002349417A CA2349417A1 (en) 1998-11-05 1999-11-05 Ikaros isoforms and mutants
JP2000579634A JP2002531066A (en) 1998-11-05 1999-11-05 IKAROS isoforms and mutants
AU18148/00A AU1814800A (en) 1998-11-05 1999-11-05 (Ikaros) isoforms and mutants
EP99961606A EP1127070A2 (en) 1998-11-05 1999-11-05 $i(IKAROS) ISOFORMS AND MUTANTS

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10722998P 1998-11-05 1998-11-05
US60/107,229 1998-11-05
US15108799P 1999-08-27 1999-08-27
US60/151,087 1999-08-27

Publications (4)

Publication Number Publication Date
WO2000026247A2 WO2000026247A2 (en) 2000-05-11
WO2000026247A3 WO2000026247A3 (en) 2000-11-16
WO2000026247A9 WO2000026247A9 (en) 2002-08-22
WO2000026247A8 true WO2000026247A8 (en) 2003-11-06

Family

ID=26804552

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/026274 WO2000026247A2 (en) 1998-11-05 1999-11-05 Ikaros isoforms and mutants

Country Status (5)

Country Link
EP (1) EP1127070A2 (en)
JP (1) JP2002531066A (en)
AU (1) AU1814800A (en)
CA (1) CA2349417A1 (en)
WO (1) WO2000026247A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101365806B (en) * 2005-12-01 2016-11-16 医学预后研究所 For identifying method and apparatus and the purposes of prediction curative effect thereof of the biomarker of therapeutic response
WO2009061890A1 (en) * 2007-11-08 2009-05-14 St. Jude Children's Research Hospital Methods and compositions for the diagnosis, prognosis and treatment of chronic myeloid leukemia and acute lymphoblastic leukemia
AU2011246976B2 (en) 2010-04-29 2016-01-28 Allarity Therapeutics Europe ApS Methods and devices for predicting treatment efficacy
DK3508589T3 (en) * 2010-09-13 2023-06-06 Clinical Genomics Pty Ltd EPIGENETIC MARKERS OF COLORECTAL CANCER AND DIAGNOSTIC PROCEDURES USING THE SAME
FI3198035T3 (en) 2014-09-26 2023-01-31 Methods for predicting drug responsiveness
US9725769B1 (en) 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
AU2017258901A1 (en) 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients
CN107034291A (en) * 2017-05-26 2017-08-11 首都医科大学附属北京儿童医院 The kit of children acute lymphoblastic leukaemia genotyping

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824770A (en) * 1992-09-14 1998-10-20 The General Hospital Corporation Ikaros polypeptides

Also Published As

Publication number Publication date
WO2000026247A3 (en) 2000-11-16
EP1127070A2 (en) 2001-08-29
JP2002531066A (en) 2002-09-24
AU1814800A (en) 2000-05-22
CA2349417A1 (en) 2000-05-11
WO2000026247A9 (en) 2002-08-22
WO2000026247A2 (en) 2000-05-11

Similar Documents

Publication Publication Date Title
WO2000028090A3 (en) Diagnostic assay for cancer
WO2000012726A3 (en) Rationally designed heparinases derived from heparinase i and ii
WO1997026270A3 (en) Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules
AU2597397A (en) Methods of recovering colorectal epithelial cells or fragments thereof from stool
HUP0100025A3 (en) Methods for treating hypercoagulable states or acquired protein c deficiency
NO982126L (en) Polymeric well compartment compositions and auxiliary compositions and methods for their use
WO2002006529A3 (en) Detection and treatment of polycystic kidney disease
AU7808198A (en) Novel compounds useful in the complement, coagulat and kallikrein pathways and method for their preparation
EP1061806A4 (en) Producer cells for replication selective viruses in the treatment of malignancy
AU6659698A (en) Compositions, methods, kits and apparatus for determining the presence or absence of target molecules
EP0985150A4 (en) Method for detecting cancer associated with altered concentrations of lysophospholipids
WO2000026247A3 (en) Ikaros isoforms and mutants
DK0760010T3 (en) Methods for screening for Crohn's disease using TNF microsatellite alleles
IL119644A (en) Rapid microbiological assay
AU1855401A (en) Screening method for candidate drugs
WO2001009384A3 (en) Serial analysis of genetic alterations
AU3444899A (en) Method for the rapid determination of bacteria
AU3028497A (en) Use of triazine-based uvas for use as quenchers in paper-making processes
AU2677095A (en) Biosensors for detecting nitrate or nitrite ions
AU3140497A (en) Methods and kits for the detection of endotoxin
ID16617A (en) WET MILLING AND MILLING PROCESSES FOR CONDUCTING THE PROCESS
AU4480997A (en) Screening methods for compounds useful in the treatment of schizophrenia
DE69837808D1 (en) pRb2 / p130 PEPTIDINHIBITORS OF cdk2 KINASEACTIVITY
WO2000066769A3 (en) System and method for screening of nasopharyngeal carcinoma
PL344785A1 (en) Methods for increasing levels of acetylcholine

Legal Events

Date Code Title Description
ENP Entry into the national phase in:

Ref country code: AU

Ref document number: 2000 18148

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 18148/00

Country of ref document: AU

ENP Entry into the national phase in:

Ref document number: 2349417

Country of ref document: CA

Ref country code: JP

Ref document number: 2000 579634

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: CA

Ref document number: 2349417

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999961606

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999961606

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999961606

Country of ref document: EP

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/13-13/13, DRAWINGS, REPLACED BY NEW PAGES 1/26-26/26; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 19/2000 DUE TO A TECHNICAL PROBLEM AT THE TIME OF INTERNATIONAL PUBLICATION, SOME INFORMATION WAS MISSING (81). THE MISSING INFORMATION NOW APPEARS IN THE CORRECTED VERSION.

Free format text: IN PCT GAZETTE 19/2000 DUE TO A TECHNICAL PROBLEM AT THE TIME OF INTERNATIONAL PUBLICATION, SOME INFORMATION WAS MISSING (81). THE MISSING INFORMATION NOW APPEARS IN THE CORRECTED VERSION.